Page last updated: 2024-12-11
eupomatenoid 5
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
eupomatenoid 5: RN given for (E)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6443783 |
CHEMBL ID | 4565833 |
MeSH ID | M0421804 |
Synonyms (14)
Synonym |
---|
eupomatenoid 5 |
phenol, 2-methoxy-4-[3-methyl-5-[(1e)-1-propenyl]-2-benzofuranyl]- |
2-methoxy-4-[3-methyl-5-[(e)-prop-1-enyl]benzofuran-2-yl]phenol |
2-methoxy-4-[3-methyl-5-[(e)-prop-1-enyl]-1-benzofuran-2-yl]phenol |
2-(4'-hydroxy-3'-methoxyphenyl)-3-methyl-5(e)-propenylbenzofuran |
41744-28-9 |
eupomatenoid-5 |
[2-(4'-hydroxy-5'-methoxyphenyl)-3-methyl-5(e)-propenylbenzofuran] |
NCGC00385078-01 |
(e)-2-methoxy-4-(3-methyl-5-(prop-1-en-1-yl)benzofuran-2-yl)phenol |
CHEMBL4565833 |
DTXSID701317176 |
2-methoxy-4-[3-methyl-5-[(e)-1-propenyl]benzofuran-2-yl]phenol |
AKOS040734921 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (8)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1514113 | Antileishmanial activity against Leishmania amazonensis MHOM/BR/75/Josefa axenic amastigotes after 72 hrs by Neubauer hemocytometric analysis | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | Leishmania treatment and prevention: Natural and synthesized drugs. |
AID1514114 | Antileishmanial activity against Leishmania amazonensis MHOM/BR/75/Josefa intracellular amastigotes after 72 hrs by Neubauer hemocytometric analysis | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | Leishmania treatment and prevention: Natural and synthesized drugs. |
AID1514112 | Antileishmanial activity against Leishmania amazonensis MHOM/BR/75/Josefa promastigotes after 72 hrs by Neubauer hemocytometric analysis | 2018 | European journal of medicinal chemistry, Dec-05, Volume: 160 | Leishmania treatment and prevention: Natural and synthesized drugs. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (12.50) | 29.6817 |
2010's | 12 (75.00) | 24.3611 |
2020's | 2 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.09
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.09) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (6.25%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (93.75%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |